Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Godavari Drugs approved audited financial results for Q4 and FY ended March 31, 2025, with an unmodified (clean) opinion from statutory auditors M/s Ayyadevara & Co. FY25 revenue from operations fell to ₹11,335.01 lakhs from ₹15,671.19 lakhs in FY24, a decline of about 27.7%. Net profit for the year dropped to ₹438.00 lakhs from ₹554.90 lakhs, with EPS at ₹5.82 vs ₹7.37. Two Independent Directors (Mr. Syed Anis Hussain and Mrs. Vimala Behram Madon) will retire on June 23, 2025 after completing their second term, and Mrs. Shilpa Bung has been appointed as a new Independent Director for 5 years. The Board also appointed new Internal, Secretarial, and Cost Auditors for FY 2025-26 and beyond. The 37th AGM is scheduled for August 28, 2025 via video conferencing. No loan or debt defaults were reported, and related party transactions (including loans from directors and remuneration) were disclosed.
Shareholders should note the sharp revenue and profit decline year-on-year, though operating cash flow remained positive at ₹1,119.60 lakhs and EBITDA margins appear to have expanded. Board refresh and new auditor appointments are routine governance matters with no immediate material impact on stock price.